The high 91% trader consensus on “No” for a new COVID variant of concern before 2027 stems from sustained low public-health risk assessments across global surveillance. As of late July 2026, neither the WHO nor ECDC lists any SARS-CoV-2 lineage as a variant of concern; monitored strains such as BA.3.2, NB.1.8.1, and XFG show no evidence of meaningfully higher severity, hospitalization, or immune escape that would trigger formal designation. Recent data through June indicate these subvariants are circulating at stable or declining levels with limited impact relative to prior waves. With only five months remaining and no accelerating signals in genomic or wastewater tracking, the market reflects the slim likelihood of rapid escalation before year-end.